Suppr超能文献

补体在免疫和炎症性疾病中的作用:治疗干预。

Complement in immune and inflammatory disorders: therapeutic interventions.

机构信息

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

出版信息

J Immunol. 2013 Apr 15;190(8):3839-47. doi: 10.4049/jimmunol.1203200.

Abstract

With the awareness that immune-inflammatory cross-talk is at the heart of many disorders, the desire for novel immunomodulatory strategies in the therapy of such diseases has grown dramatically. As a prime initiator and important modulator of immunological and inflammatory processes, the complement system has emerged as an attractive target for early and upstream intervention in inflammatory diseases and has moved into the spotlight of drug discovery. Although prevalent conditions such as age-related macular degeneration have attracted the most attention, the diverse array of complement-mediated pathologies, with distinct underlying mechanisms, demands a multifaceted arsenal of therapeutic strategies. Fortunately, efforts in recent years have not only introduced the first complement inhibitors to the clinic but also filled the pipelines with promising candidates. With a focus on immunomodulatory strategies, in this review we discuss complement-directed therapeutic concepts and highlight promising candidate molecules.

摘要

由于认识到免疫炎症的相互作用是许多疾病的核心,因此人们对这些疾病治疗中新型免疫调节策略的需求急剧增加。补体系统作为免疫和炎症过程的主要启动者和重要调节剂,已成为炎症性疾病早期和上游干预的一个有吸引力的靶点,并成为药物发现的焦点。尽管像年龄相关性黄斑变性这样的常见疾病引起了最多的关注,但由于不同的补体介导的病理具有不同的潜在机制,因此需要多种治疗策略。幸运的是,近年来的努力不仅将第一种补体抑制剂引入临床,而且还为有前途的候选药物填充了研发管线。本文重点讨论了免疫调节策略,讨论了补体靶向治疗的概念,并强调了有前途的候选分子。

相似文献

1
Complement in immune and inflammatory disorders: therapeutic interventions.
J Immunol. 2013 Apr 15;190(8):3839-47. doi: 10.4049/jimmunol.1203200.
2
Complement in age-related macular degeneration: a focus on function.
Eye (Lond). 2011 Jun;25(6):683-93. doi: 10.1038/eye.2011.37. Epub 2011 Mar 11.
3
Complement in immune and inflammatory disorders: pathophysiological mechanisms.
J Immunol. 2013 Apr 15;190(8):3831-8. doi: 10.4049/jimmunol.1203487.
5
Complement deficiencies.
Pediatr Clin North Am. 2000 Dec;47(6):1339-54. doi: 10.1016/s0031-3955(05)70274-1.
6
[The complement system--structure, activation, regulation and function].
Tidsskr Nor Laegeforen. 1999 Jan 20;119(2):226-33.
7
The complement cascade in kidney disease: from sideline to center stage.
Am J Kidney Dis. 2013 Sep;62(3):604-14. doi: 10.1053/j.ajkd.2012.12.033. Epub 2013 Mar 13.
9
[The complement system as a mediator of acute inflammation].
Dtsch Tierarztl Wochenschr. 1983 Sep 8;90(9):374-7.
10
Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
Front Immunol. 2018 Aug 8;9:1851. doi: 10.3389/fimmu.2018.01851. eCollection 2018.

引用本文的文献

3
Renal Epithelial Complement C3 Expression Affects Kidney Fibrosis Progression.
Int J Mol Sci. 2024 Nov 22;25(23):12551. doi: 10.3390/ijms252312551.
4
TMT-based proteomics analysis of the blood enriching mechanism of the total Tannins of Gei Herba in mice.
Heliyon. 2024 Jun 17;10(12):e33212. doi: 10.1016/j.heliyon.2024.e33212. eCollection 2024 Jun 30.
6
Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee.
J Vitreoretin Dis. 2023 Dec 21;8(1):9-20. doi: 10.1177/24741264231220224. eCollection 2024 Jan-Feb.
9
Complement: Functions, location and implications.
Immunology. 2023 Oct;170(2):180-192. doi: 10.1111/imm.13663. Epub 2023 May 24.

本文引用的文献

1
Complement in immune and inflammatory disorders: pathophysiological mechanisms.
J Immunol. 2013 Apr 15;190(8):3831-8. doi: 10.4049/jimmunol.1203487.
2
Targeting complement at the time of transplantation.
Adv Exp Med Biol. 2013;735:247-55. doi: 10.1007/978-1-4614-4118-2_17.
5
Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
Am J Kidney Dis. 2013 Feb;61(2):289-99. doi: 10.1053/j.ajkd.2012.07.028. Epub 2012 Nov 7.
6
Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating.
Biomaterials. 2013 Jan;34(4):985-94. doi: 10.1016/j.biomaterials.2012.10.040. Epub 2012 Nov 5.
8
Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.
Circulation. 2012 Oct 30;126(18):2227-35. doi: 10.1161/CIRCULATIONAHA.112.123968. Epub 2012 Oct 2.
9
Progress and Trends in Complement Therapeutics.
Adv Exp Med Biol. 2013;735:1-22. doi: 10.1007/978-1-4614-4118-2_1.
10
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Immunobiology. 2012 Nov;217(11):1080-7. doi: 10.1016/j.imbio.2012.07.014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验